Lidocaine 5% patch in the treatment of localized neuropathic pain due to nerve compression. Case reports
Emplastro de lidocaína a 5% no tratamento da dor neuropática localizada por compressão nervosa. Relato de casos
André Liggieri; Mariana Palladini
Abstract
BACKGROUND AND OBJECTIVES: Neuropathic pain is a chronic condition with a significant burden for patients, society, and healthcare systems. Due to neuropathic complexity, its management must be different than the one for nociceptive pain. First-line systemic treatments may be associated with dose-dependent adverse events and drug-drug interactions. On the other hand, topical treatments have less systemic adverse events, with the 5% lidocaine transdermal patch being recommended for first- or second line of treatment for neuropathic pain according to various international guidelines. The aim of this study is to present three cases of localized neuropathic pain due to nerve compression managed with 5% lidocaine transdermal patch.
CASE REPORTS: The cases of three adult patients (>40 years old) with pain or tingling for a long period of time and their outcomes with treatment with 5% lidocaine transdermal patch for a prolonged duration were investigated. All three cases report a significant improvement in pain.
CONCLUSION: The results of the reported cases revealed that a 5% lidocaine transdermal patch represents an effective, safe and tolerable and noninvasive option for the management of localized neuropathic pain due to peripheric nerve compression.
Keywords
Resumo
JUSTIFICATIVA E OBJETIVOS: A dor neuropática é uma condição crônica com impactos significativos para o paciente, a sociedade e o sistema de saúde. Pela sua complexidade neuropática, a sua abordagem deve ser diferente da dor nociceptiva. Os tratamentos sistêmicos de primeira linha para a dor neuropática podem estar associados à incidência de eventos adversos dose-dependentes e interações farmacológicas. Por outro lado, os fármacos tópicos apresentam menor incidência de eventos adversos sistêmicos, sendo o emplastro de lidocaína a 5% recomendado como primeira ou segunda linha de tratamento para essa condição em diversos guidelines internacionais. O objetivo deste estudo foi apresentar três casos clínicos de dor neuropática localizada por compressão nervosa manejados com o emplastro de lidocaína a 5%.
RELATO DOS CASOS: Três pacientes com idade superior a 40 anos e queixas de dor ou parestesia de longa duração foram manejados com emplastro de lidocaína a 5% em tratamento prolongado, com melhora da intensidade de dor expressiva.
CONCLUSÃO: Os resultados dos casos reportados revelaram que o emplastro de lidocaína a 5% se apresentou como uma opção terapêutica eficaz, segura, bem tolerada e não invasiva no manejo da dor neuropática localizada por compressão nervosa periférica.
Palavras-chave
References
1 Cruccu G, Truini A. A review of neuropathic pain: from guidelines to clinical practice. Pain Ther. 2017;6(Suppl 1):35-42.
2 Pickering G, Martin E, Tiberghien F, Delorme C, Mick G. Localized neuropathic pain: an expert consensus on local treatments. Drug Des Devel Ther. 2017;11:2709-18.
3 Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, Freeman R, Truini A, Attal N, Finnerup NB, Eccleston C, Kalso E, Bennett DL, Dworkin RH, Raja SN. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002.
4 Likar R, Demschar S, Kager I, Neuwersch S, Pipam W, Sittl R. Treatment of localized neuropathic pain of different etiologies with the 5% lidocaine medicated plaster - a case series. Int J Gen Med. 2015;8:9-14.
5 Mick G, Baron R, Correa-Illanes G, Hans G, Mayoral V, Frías X, Sintes D, Keller T. Is an easy and reliable diagnosis of localized neuropathic pain (LNP) possible in general practice? Development of a screening tool based on IASP criteria. Curr Med Res Opin. 2014;30(7):1357-66.
6 Mick G, Baron R, Finnerup NB, Hans G, Kern KU, Brett B, Dworkin RH. What is localized neuropathic pain? A first proposal to characterize and define a widely used term. Pain Manag. 2012;2(1):71-7.
7 Mayoral V, Pérez-Hernández C, Muro I, Leal A, Villoria J, Esquivias A. Diagnostic accuracy of an identification tool for localized neuropathic pain based on the IASP criteria. Curr Med Res Opin. 2018;34(8):1465-73.
8 Santos JG, Brito JO, de Andrade DC, Kaziyama VM, Ferreira KA, Souza I, Teixeira MJ, Bouhassira D, Baptista AF. Translation to portuguese and validation of the Douleur Neuropathique 4 questionnaire. J Pain. 2010;11(5):484-90.
9 Moisset X, Bouhassira D, Avez Couturier J, Alchaar H, Conradi S, Delmotte MH, Lanteri-Minet M, Lefaucheur JP, Mick G, Piano V, Pickering G, Piquet E, Regis C, Salvat E, Attal N. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Rev Neurol (Paris). 2020;176(5):325-52.
10 Allegri M, Baron R, Hans G, Correa-Illanes G, Mayoral Rojals V, Mick G, Serpell M. A pharmacological treatment algorithm for localized neuropathic pain. Curr Med Res Opin. 2016;32(2):377-84.
11 Goddard JM, Reaney RL. Lidocaine 5%-medicated plaster (Versatis) for localised neuropathic pain: results of a multicentre evaluation of use in children and adolescents. Br J Pain. 2018;12(3):189-93.
12 Nair AS, Mantha SSP, Azharuddin M, Rayani BK. Lidocaine 5% patch in localized neuropathic pain. Indian J Palliat Care. 2019;25(4):594-5.
13 Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;2014(7):CD010958.
14 Gagnier JJ, Kienle G, Altman DG. Moher D, Sox H, Riley D; CARE Group. The CARE guidelines: consensus-based clinical case reporting guideline development. Gob Adv Health Med. 2013;2(5):38-43.
15 Kocot-Kępska M, Zajączkowska R, Mika J, Kopsky DJ, Wordliczek J, Dobrogowski J, Przeklasa-Muszyńska A. Topical treatments and their molecular/cellular mechanisms in patients with peripheral neuropathic pain-narrative review. Pharmaceutics. 2021 Mar 26;13(4):450.
16 Gudin J, Webster LR, Greuber E, Vought K, Patel K, Kuritzky L. Open-label adhesion performance studies of a new lidocaine topical system 1.8% versus lidocaine patches 5% and lidocaine medicated plaster 5% in healthy subjects. J Pain Res. 2021;14:513-26.
17 Hans G, Robert D, Verhulst J, Vercauteren M. Lidocaine 5% patch for localized neuropathic pain: progress for the patient, a new approach for the physician. Clin Pharmacol. 2010;2:65-70.
18 Nalamachu S, Crockett RS, Gammaitoni AR, Gould EM. A comparison of the lidocaine patch 5% vs naproxen 500 mg twice daily for the relief of pain associated with carpal tunnel syndrome: a 6-week, randomized, parallel-group study. Med Gen Med. 2006;8(3):33.
19 Nalamachu S, Crockett RS, Mathur D. Lidocaine patch 5 for carpal tunnel syndrome: how it compares with injections: a pilot study. J Fam Pract. 2006 Mar;55(3):209-14.
Submitted date:
08/05/2022
Accepted date:
07/24/2023
Facebook
Google+
Twitter
LinkedIn
Mendeley
Email